Katherine A Fu1, Kimberly C Paul2, Ake T Lu3, Steve Horvath4, Adrienne M Keener5, Yvette Bordelon6, Jeff M Bronstein6, Beate Ritz7. 1. Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA. Electronic address: kfu@mednet.ucla.edu. 2. Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA 90095, USA. 3. Department of Human Genetics, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA. 4. Department of Human Genetics, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA; Department of Biostatistics, UCLA Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA. 5. Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA; Department of Neurology, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. 6. Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA. 7. Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA; Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA 90095, USA. Electronic address: britz@ucla.edu.
Abstract
BACKGROUND: The epigenome may reflect Parkinson's disease (PD) risk, which serves as a point of convergence of genetic and environmental risk factors. Here, we investigate whether blood DNA methylation (DNAm) markers are associated with PD risk. METHODS: We selected 12 plasma proteins known as predictors of cardiovascular conditions and mortality to evaluate their effects on PD risk in a case-control study. In lieu of protein level measures, however, we assessed the influence of their DNAm surrogates. Primary analysis was restricted to 569 PD patients and 238 controls with DNAm data available. Using univariate logistic regression, we evaluated associations between the DNAm markers and PD. RESULTS: Of the 12 DNAm surrogates, the most robustly associated were DNAm EFEMP-1 and DNAm CD56, which were associated with PD with and without controlling for blood cell composition. DNAm EFEMP-1 was associated with a decreased risk of PD (OR = 0.83 per SD, 95% CI = 0.70, 0.98) whereas DNAm CD56 was associated with an increased risk of PD (OR = 1.41, 95% CI = 1.11, 1.79). CONCLUSIONS: Several DNAm markers, selected as part of a panel to track cardiovascular outcomes and mortality, were associated with PD risk. DNAm markers may inform of factors that are affected differentially in early PD patients compared with controls. Published by Elsevier B.V.
BACKGROUND: The epigenome may reflect Parkinson's disease (PD) risk, which serves as a point of convergence of genetic and environmental risk factors. Here, we investigate whether blood DNA methylation (DNAm) markers are associated with PD risk. METHODS: We selected 12 plasma proteins known as predictors of cardiovascular conditions and mortality to evaluate their effects on PD risk in a case-control study. In lieu of protein level measures, however, we assessed the influence of their DNAm surrogates. Primary analysis was restricted to 569 PD patients and 238 controls with DNAm data available. Using univariate logistic regression, we evaluated associations between the DNAm markers and PD. RESULTS: Of the 12 DNAm surrogates, the most robustly associated were DNAm EFEMP-1 and DNAm CD56, which were associated with PD with and without controlling for blood cell composition. DNAm EFEMP-1 was associated with a decreased risk of PD (OR = 0.83 per SD, 95% CI = 0.70, 0.98) whereas DNAm CD56 was associated with an increased risk of PD (OR = 1.41, 95% CI = 1.11, 1.79). CONCLUSIONS: Several DNAm markers, selected as part of a panel to track cardiovascular outcomes and mortality, were associated with PD risk. DNAm markers may inform of factors that are affected differentially in early PD patients compared with controls. Published by Elsevier B.V.
Entities:
Keywords:
Cardiovascular disease; DNA methylation; Disease risk; Epigenetics; Parkinson's disease
Authors: Emanuela Colla; Philippe Coune; Ying Liu; Olga Pletnikova; Juan C Troncoso; Takeshi Iwatsubo; Bernard L Schneider; Michael K Lee Journal: J Neurosci Date: 2012-03-07 Impact factor: 6.167
Authors: Eugene Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Carmen J Marsit; Heather H Nelson; John K Wiencke; Karl T Kelsey Journal: BMC Bioinformatics Date: 2012-05-08 Impact factor: 3.169
Authors: Yu-Hsuan Chuang; Kimberly C Paul; Jeff M Bronstein; Yvette Bordelon; Steve Horvath; Beate Ritz Journal: Genome Med Date: 2017-08-30 Impact factor: 11.117
Authors: Ake T Lu; Austin Quach; James G Wilson; Alex P Reiner; Abraham Aviv; Kenneth Raj; Lifang Hou; Andrea A Baccarelli; Yun Li; James D Stewart; Eric A Whitsel; Themistocles L Assimes; Luigi Ferrucci; Steve Horvath Journal: Aging (Albany NY) Date: 2019-01-21 Impact factor: 5.682